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Introduction
IL-33 is a cytokine abundantly expressed at mucosal barriers (1) that has been shown to promote type 2–
polarized immune programs in health and disease (2, 3). A role for IL-33 in human type 2–driven chronic 
airway disease was highlighted by genome-wide association studies linking IL33 and IL1RL1/ST2 with 
asthma (4–6) and increased IL-33 in serum, sputum, or tissue from patients with asthma (7, 8) and patients 
with chronic obstructive pulmonary disease (COPD) (9–11). Animal models have also supported a role 
for IL-33 in response to virus (9) or allergen (12, 13) triggers of  airway disease. The IL-33 system is also 
broadly linked to pulmonary inflammation, arthritis, inflammatory bowel disease, hepatitis, heart failure, 
central nervous system inflammation, and cancer (reviewed in ref. 2). This wide-ranging disease relevance 
emphasizes the necessity of  understanding how a nuclear-targeted cytokine, or “nucleokine,” lacking a 
classical secretion signal can be released from intact cells to propagate inflammation.
Human full-length IL-33 (IL-33full) is a 270–amino acid protein encoded by 8 exons that encompass 
the N-terminal “chromatin-interacting” domain (NTD) and C-terminal “cytokine” domain (CTD). The 
NTD chromatin-interacting motif  (14) appears to be responsible for tightly sequestering IL-33 within the 
nucleus, presumably to regulate the cytokine, as a specific nuclear function for IL-33full protein has yet to be 
firmly established (15). The CTD includes exons 5–8 and is sufficient to induce signaling through the IL-33 
receptor (IL-1RL1/ST2 and IL-1RAP) (16). Unlike the prototypic IL-1 family member, IL-1β, IL-33 is not 
cleaved by inflammasome-associated caspases (17, 18). Apoptotic and inflammatory proteases can process 
IL-33full in vitro, which can result in either enhanced function (19) or deactivation (20, 21). While these in 
vitro studies have shown that processed cytokine retains activity, it remains unknown whether proteolysis 
is required for activation or secretion of  endogenous IL-33 in vivo.
IL-33 is a key mediator of chronic airway disease driven by type 2 immune pathways, yet the 
nonclassical secretory mechanism for this cytokine remains undefined. We performed a 
comprehensive analysis in human airway epithelial cells, which revealed that tonic IL-33 secretion 
is dependent on the ceramide biosynthetic enzyme neutral sphingomyelinase 2 (nSMase2). IL-33 
is cosecreted with exosomes by the nSMase2-regulated multivesicular endosome (MVE) pathway 
as surface-bound cargo. In support of these findings, human chronic obstructive pulmonary 
disease (COPD) specimens exhibited increased epithelial expression of the abundantly secreted 
IL33Δ34 isoform and augmented nSMase2 expression compared with non-COPD specimens. Using 
an Alternaria-induced airway disease model, we found that the nSMase2 inhibitor GW4869 
abrogated both IL-33 and exosome secretion as well as downstream inflammatory pathways. This 
work elucidates a potentially novel aspect of IL-33 biology that may be targeted for therapeutic 
benefit in chronic airway diseases driven by type 2 inflammation.
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IL-33 secretion has been investigated under multiple conditions, and two primary scenarios have 
unfolded in the literature (reviewed in ref. 22): passive “alarmin” release from necrotic cells during tissue 
damage and nonclassical secretion from intact cells. In the context of  airway disease, passive IL-33 release 
could occur with acute airway damage, but this transient activity is unlikely to account for maintenance 
of  chronic disease. A mechanism based on nonclassical secretion appears to be the more likely basis for 
persistent IL-33 activity. Support for this mechanism is provided by the recent description of  natural spliced 
IL33 isoforms lacking portions of  the NTD (23, 24), which may not be regulated by nuclear sequestration.
To investigate the mechanism of  epithelial IL-33 secretion in chronic airway disease, we took advantage 
of  the properties of  these truncated IL33 isoforms. We expressed IL-33 protein variants in primary human 
airway basal cells as dual-fluorescence and peptide-tagged fusion proteins, demonstrating secretion of  intact 
protein through the neutral sphingomyelinase-2–dependent (nSMase2-dependent) multivesicular endosome 
(MVE) pathway. IL-33 can be cosecreted noncovalently bound to small extracellular vesicles (EVs) (approxi-
mately 100–150 nm diameter) commonly referred to as exosomes (25). We also leveraged COPD specimens 
to investigate this pathway and found the IL-33 isoform lacking NTD exons 3 and 4 (IL33Δ34) and nSMase2 
were increased in COPD-derived specimens relative those in non-COPD controls. IL-33 was isolated from 
COPD bronchial wash (BW) fluid, and the primary species present was a truncated, bioactive form with 
immunoreactivity consistent with the IL-33Δ34 variant. Using an Alternaria-induced model of  airway disease, 
we demonstrated that blockade of  nSMase2 with GW4869 resulted in reduced IL-33 and exosome secretion 
in bronchoalveolar lavage (BAL) fluid and downstream type 2 inflammation. Together, these data reveal a 
mechanism for IL-33 secretion from intact airway cells and demonstrate a potential avenue for the develop-
ment of  novel therapeutics in type 2 endotypes of  chronic airway disease driven by this cytokine pathway.
Results
Tonic secretion of  truncated IL-33 variants from intact airway cells. We leveraged a series of known N-terminal trun-
cated IL33 isoforms (23, 24) lacking exons 3–5 (Figure 1A) to investigate the mechanism of nonclassical secre-
tion from intact airway epithelial cells. We transduced airway basal cells with lentiviruses expressing dual-tagged 
IL-33 fusion proteins, comprising either N-terminal mCherry and C-terminal monomeric eGFP (mCherry-IL-
33-GFP) or N-terminal Flag and C-terminal 6-His tags (Flag-IL-33-His) (Figure 1B). This strategy allowed 
simultaneous tracking of N- and C-terminal fragments, should proteolysis occur in the process of secretion. 
We imaged live COPD basal cells (Figure 1C) and stable HBE-1 cell lines (Supplemental Figure 1, A and 
B; supplemental material available online with this article; https://doi.org/10.1172/jci.insight.136166DS1) 
expressing mCherry-IL-33-GFP fusion proteins, including IL-33full, single-exon deletion variants (IL-33Δ3, 
IL-33Δ4, IL-33Δ5), compound deletion variants (IL-33Δ34 and IL-33Δ345), and a nonnatural IL-33Δ2 variant (for 
comparison). Results demonstrated tight nuclear mCherry and GFP signal for IL-33full and all single-exon dele-
tion variants. In contrast, the compound deletion variants exhibited mixed nuclear and cytoplasmic staining, 
as apparent by both epifluorescence (Figure 1C) and confocal imaging (Supplemental Figure 1B). The strict 
merged signal for all variants indicated that proteins were intact within respective cellular compartments.
To determine whether altered cellular localization affected IL-33 secretion efficiency, we performed 
IL-33 ELISA on cell supernatants and lysates for epithelial cells expressing IL-33 variants as both mCher-
ry-GFP and Flag-His fusions (Figure 1, D and E, and Supplemental Figure 1, C–E). In both COPD and 
non-COPD basal cells as well as the epithelial HBE-1 cell line, we found that IL-33Δ34 exhibited the most 
abundant protein expression and tonic secretion among the isoforms tested. When normalized to account 
for differences in protein expression levels (percentage secreted, Figure 1E and Supplemental Figure 1, C 
and D), IL-33Δ34 was still secreted more efficiently than any other variant, a finding which was stable over a 
10-fold range of  total protein expression (Figure 1F). The IL-33Δ345 variant also exhibited increased secretion 
efficiency, but total expression was well below other variants and near assay detection limits.
We also tested vectoral secretion of  IL-33full and IL-33Δ34 from non-COPD basal cells assayed in 
polarized format (Figure 1G). Flag-IL-33-His secretion was measured in apical and basal compartments 
of  confluent cultures grown on Transwell supports, which showed that IL-33full and IL-33Δ34 were secret-
ed in both directions but more abundantly from the apical surface. Similar to the nonpolarized format, 
the IL-33Δ34 variant was secreted more efficiently (2-fold) over IL-33full. Results were not influenced by the 
pore sizes in the Transwell support (Figure 1G and Supplemental Figure 1F).
To investigate the role of  proteolysis in tonic secretion, we analyzed Flag-immunoprecipitat-
ed (Flag-IP) Flag-IL-33Δ34-His from cell supernatants by anti-6His Western blot (Figure 1H). Flag-IP 
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IL-33Δ34 protein from supernatant migrated at the same MW as protein from cell lysate and was detect-
ed by anti-6His Western blot, indicating that secreted protein was intact (not proteolytically processed). 
This is consistent with imaging of  mCherry-IL-33-GFP isoforms, which demonstrated merged signal in 
both nuclear and cytoplasmic compartments.
Figure 1. Tonic secretion of IL-33 from airway epithelial cells. (A) Human IL33 exon structure with N-terminal domain (orange), interdomain linker (cyan), and 
C-terminal domain (magenta). (B) Schematic of human IL-33 fusion protein reagents cloned with either dual-fluorescence (N-terminal mCherry and C-terminal 
GFP) tags or dual-peptide (N-terminal Flag and C-terminal 6xHis) tags. (C) Live-cell imaging of COPD airway basal cells transduced with lentiviruses expressing 
the following mCherry-IL-33-GFP variants: full length (Full) or truncated lacking single exons 2–5 (Δ2, Δ3, Δ4, and Δ5) or multiple exons (Δ34 and Δ345). Cyto-
plasmic yellow (merged) staining is shown for Δ34 and Δ345 variants; Hoechst 33342 counterstain was also used. Scale bar: 10 μm. (D and E) ELISA secretion 
assay performed for mCherry-GFP and Flag-His IL-33 variants in non-COPD and COPD airway basal cells (n = 5). Solid colored bars show measurement with R&D 
monoclonal assay, and bars with angled stripes (Δ5 and Δ345) indicate measurement with polyclonal assay (due to lack of monoclonal epitope located in exon 
5). (F) Secretion assay for Flag-IL-33Δ34-His, demonstrating that the percentage of secretion is stable over a 10-fold expression range in non-COPD cells (n = 5). 
(G) Secretion assay in polarized format for non-COPD cells expressing full-length Flag-IL-33full-His and truncated Flag-IL-33Δ34-His variants (n = 3). Protein was 
detected in both apical and basal fractions, with apical predominance as both concentration and percentage secreted. (H) Flag IP of Flag-IL-33Δ34-His from COPD 
cell supernatant. Lanes: cell lysate (lys), supernatant (sup), and Flag-IP supernatant (elute) detected by anti-6His Western blot demonstrating intact (unpro-
cessed) secreted protein. Data are shown as the mean ± SEM. Statistical analysis: 1-way ANOVA (D and E) and t test (G); *P < 0.05, **P < 0.01, ***P < 0.001.
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Together, these results demonstrate that the protein product of the natural IL33Δ34 isoform can be abun-
dantly expressed in airway basal cells, exhibits cytoplasmic accumulation due to lack of nuclear targeting, and 
is tonically secreted at high levels preferentially from the apical surface without proteolytic processing. These 
findings support a model in which IL33 isoforms with altered cellular localization are released from nuclear 
regulation to undergo tonic secretion from the base of the epithelium predominantly toward the airway lumen.
Epithelial IL-33 and exosomes are secreted through the nSMase2-dependent MVE pathway. The protein prod-
ucts of  all IL33 isoforms lack a signal sequence to mediate secretion via the ER/Golgi pathway, therefore 
the tonic secretion observed in our cellular assay must occur via a nonclassical mechanism. Multiple routes 
of  nonclassical protein secretion have been described, including active transporters (26), cell death–induc-
ing membrane pores (27), plasma membrane shedding (microvesicles), or through incorporation into mul-
tivesicular endosomes (MVE) that fuse with the cell surface to release small intraluminal EVs or “exo-
somes” containing protein and miRNA cargo (28).
To address which nonclassical secretion pathway was involved, we tested a panel of  chemical inhibitors 
with our IL-33 ELISA secretion assay. We performed inhibition experiments in non-COPD and COPD 
basal cells and HBE-1 cells expressing Flag-IL-33Δ34-His and mCherry-IL-33Δ34-GFP (Figure 2A and Supple-
mental Figure 2, A and B). The ER-Golgi inhibitors brefeldin and monensin had no effect on secretion; how-
ever, we did observe a marked inhibition of  IL-33Δ34 secretion following treatment with GW4869, a noncom-
petitive antagonist of  the ceramide synthetic enzyme neutral sphingomyelinase 2 (nSMase2) (29) (Figure 
2A). GW4869 was found to inhibit IL-33Δ34 secretion in both non-COPD and COPD basal cells and HBE-1 
cells, which was apparent as both the amount and percentage secreted (Figure 2A and Supplemental Figure 
2, A and B). Other putative nSMase2 inhibitors, spiroepoxide (29), glutathione (29), and cambinol (30), and 
the microautophagy inhibitor 3-methyladenine (3-MA) (31) exhibited a modest effect on secretion, which 
was variably significant among non-COPD, COPD, and HBE-1 cells tested. When GW4869 was tested 
against the panel of  IL-33 variants in COPD cells, it was found to globally inhibit secretion for variants that 
exhibit distinct cellular localization patterns and expression levels (Figure 2B and Supplemental Figure 2C).
The ceramide biosynthetic enzyme nSMase2 (SMPD3) regulates the ESCRT-independent MVE path-
way through maturation and membrane fusion of  MVEs (29). Our observed inhibition of  tonic epitheli-
al IL-33 secretion with the compound GW4869 suggested that this phenomenon may be dependent on 
nSMase2 activity. We first examined SMPD3 expression in airway basal cells, which revealed significantly 
increased expression in COPD specimens relative to that in non-COPD specimens (Figure 2C). nSMase2 
enzyme activity was measured in a subset of  cultured cell lysates, and multiple COPD specimens exhibited 
increased activity compared with non-COPD specimens. Given these findings, we targeted the nSMase2- 
dependent MVE pathway with shRNA knockdown and compared with mediators of  the ESCRT-dependent 
MVE (VPS4A) (32) and microautophagy (LAMP2) (33) pathways. Experiments using primary cells also 
included the ROCK inhibitor Y27632, which functions to block microvesicle shedding from the plasma 
membrane (34). In COPD cells, we performed serial rounds of  transduction with shRNA- and Flag-IL-
33Δ34-His–expressing lentiviruses, followed by selection and recovery (Figure 2D). Successful knockdown 
of  targets was confirmed by qPCR (Supplemental Figure 2E). We were careful to fully recover cells before 
secretion assay to avoid ongoing cell death from selection complicating interpretation. Subsequent IL-33 
secretion assay demonstrated a 2-fold reduction in IL-33Δ34 secretion only with nSMase2 shRNA knock-
down, based on both absolute and percentage secretion (Figure 2D and Supplemental Figure 2D). As a con-
firmatory approach, we developed an HBE-1 SMPD3–/– cell line, which revealed further (3-fold) reduction in 
IL-33Δ34 absolute and percentage secretion (Figure 2D and Supplemental Figure 2G). COPD cells express-
ing Flag-IL-33Δ34-His were also immunostained with anti-Flag and corresponding antibodies for VPS4A, 
LAMP2, and nSMase2, demonstrating a vesicular staining pattern for pathway intermediates and diffuse 
nucleocytoplasmic staining for IL-33Δ34 (Figure 2E). Immunostaining was also performed in cells expressing 
nSMase2 shRNA and Flag-IL-33Δ34-His, which demonstrated a loss of  nSMase2 staining and an accumula-
tion of  cytoplasmic IL-33Δ34 (and loss of  nuclear staining).
To investigate the effect of nSMase2 knockdown on EV production, we analyzed EVs secreted from COPD 
cells (Figure 2F). Culture supernatants were concentrated using a 100 kDa cutoff centrifugal filter, and the con-
centrations of particles with diameters of less than 150 nm were measured by tunable resistive pulse sensing 
(TRPS, Figure 2F and Supplemental Figure 3A). Secreted EVs were notably increased 10-fold with VPS4A 
knockdown but undetectable (<107 particles/ml) for nSMase2 (Figure 2F). Particle size histograms revealed that 
mean EV size for control cells was 125 nm, consistent with that of exosomes, which was shifted slightly larger 
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Figure 2. nSMase2 regulates tonic IL-33 and exosome secretion from epithelial cells. (A) ELISA secretion assay for Flag-IL-33Δ34-His COPD and non-COPD 
airway basal cells treated with chemical inhibitors (concentrations in Methods), PBS, DMSO vehicle control, and Golgi (brefeldin and monensin); vesicle path-
way inhibitors (GW4869, cambinol, spiroepoxide, and glutathione); and microautophagy inhibitors (3-methyladenine [3-MA]), showing marked blockade with 
GW4869 (n = 5). (B) COPD cells treated with DMSO or GW4869 (20 μM), demonstrating inhibition for all IL-33 variants (n = 3–5). (C) qPCR for SMPD3 mRNA in n 
= 12 non-COPD and n = 22 COPD cell specimens and nSMase2 enzyme activity for a subset (n = 6 non-COPD, n = 12 COPD), demonstrating increased expression 
in COPD. (D) shRNA knockdown in COPD cells and SMPD3–/– HBE-1 cells, showing decreased Flag-IL-33Δ34-His secretion with nSMase2 shRNA, which was fur-
ther reduced in SMPD3–/– HBE-1 cells (n = 5). (E) COPD cells expressing Flag-IL33Δ34-His immunostained for VPS4A, LAMP2, or nSMase2 (green) and Flag (red). 
Coexpression of nSMase2 shRNA demonstrates loss of staining; Hoechst 33342 nuclear counterstain was also used. Scale bar: 10 μm. (F) Secreted exosomes 
(<150 nm) from shRNA knockdown cells quantified by tunable resistive pulse sensing (TRPS), demonstrating increased particles for VPS4A. #Undetectable 
for nSMase2 (detection limit 1 × 107 particles/ml). (G) Dynamic light scattering (DLS) particle size distribution on same samples with a larger peak shift for 
nSMase2 shRNA. (H) SMPD3 qPCR demonstrating increased relative expression in airway basal cells compared with HMC1.2 mast cell line (n = 3). (I) HMC1.2 
cells expressing Flag-IL-33Δ34-His demonstrate no tonic secretion (ND) despite measurable total protein in lysate (n = 3). Data are shown as the mean ± SEM. 
Statistical analysis: 1-way ANOVA (A and COPD in D) and t test (B, C, H, and HBE-1 in D); *P < 0.05, **P < 0.01, ***P < 0.001.
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with VPS4A or LAMP2 knockdown. Because TRPS analysis is limited to a pre-determined size range, we also 
analyzed EVs with dynamic light scattering (DLS), which showed that particle histograms shifted to be larger 
with VPS4A knockdown; this size increase shifted further with LAMP2 knockdown and exceeded exosome 
size range with nSMase2 knockdown (Figure 2G and Supplemental Figure 3D). For all shRNA knockdown 
conditions, vesicles exhibited increased heterogeneity based on the polydispersity index compared with control, 
suggesting that disruption of any pathway intermediate could have global effects on vesicle biogenesis.
We also sought to determine whether this is a general phenomenon, as IL-33 expression has been report-
ed in multiple cell types, including some immune cell populations (13, 35). We found that the human mast 
cell line HMC 1.2 exhibited 150-fold lower SMPD3 expression compared with that of  airway basal cells 
(Figure 2H) and, therefore, transduced these cells with Flag-IL-33Δ34-His and performed secretion assay. 
Despite adequate cellular protein expressed in cell lysate, no IL-33Δ34 protein could be detected in cell super-
natants, including under GW4869 treatment conditions (Figure 2I).
Together, these data reveal that tonic epithelial IL-33Δ34 secretion can be blocked by nSmase2 inhibition 
using both pharmacologic and genetic approaches. Coupled with reduction in secreted exosomes under 
these same conditions, this strongly implicates the nSMase2-dependent exosome biogenesis pathway in 
nonclassical IL-33 secretion. Parallel analysis in other cell types further suggests that IL-33 secretion could 
be a specialized function of  nSMase2-expressing cells.
Augmenting nSMase2 promotes IL-33 secretion. We used the nSMase2 activator 4-methylumbelliferone (4-MU, 
ref. 36) to determine whether modulation of nSMase2 activity could promote IL-33Δ34 secretion. Treatment of  
Flag-IL-33Δ34-His expressing COPD cells resulted in a 2-fold increase in secreted IL-33Δ34 protein and a 10% 
increase in secretion efficiency, which could be reversed using the noncompetitive nSMase2 inhibitor GW4869 
(Figure 3A). Live-cell imaging of the mCherry-IL-33Δ34-GFP HBE-1 line treated with both the nSMase2 activa-
tor 4-MU and GW4869 in an effort to trap MVEs at the point of secretion demonstrated foci of merged IL-33 
signal near the plasma membrane (Figure 3B). Cells were then fixed under the same conditions and immu-
nostained for the exosome marker CD9, which demonstrated that these IL-33-GFP foci also contained CD9.
In contrast to IL-33Δ34, IL-33full appears to be tightly sequestered in the nuclei of  airway cells. We next 
asked whether altered cytoplasmic trafficking of  IL-33full could drive secretion of  this variant through the 
nSMase2-dependent MVE pathway. We tested this under conditions of  nuclear import inhibition with iver-
mectin (37) and with the nSMase2 activator 4-MU. With ivermectin treatment, we observed an approximately 
2-fold increase in secreted IL-33full protein (Figure 3C), which could be reversed by GW4869. Likewise, 4-MU 
induced a 3-fold enhancement of  Flag-IL-33full-His secretion, which was also sensitive to GW4869, suggesting 
that both nuclear import blockade and nSMase2 activation function to shunt cytoplasmic IL-33full toward the 
MVE secretory pathway. To visualize altered trafficking of  IL-33full, the mCherry-IL-33full-GFP HBE-1 line 
was treated with both of  ivermectin and 4-MU and live-cell imaging was performed, which demonstrated 
accumulation of  cytoplasmic mCherry-IL-33full-GFP signal, with sustained signal within the nucleus (Figure 
3D). We interpret these results as augmented secretion due to altered trafficking of  newly synthesized (overex-
pressed) IL-33full protein rather than cytoplasmic translocation of  nuclear sequestered protein.
These data would suggest that recruitment of  IL-33 protein to the nSMase2-dependent MVE pathway 
could occur for any IL33 isoform expressed under cellular conditions where the cytokine accumulates with-
in the cytoplasm and that nSMase2 activation can enhance secretion efficiency accordingly.
IL-33Δ34 is secreted with exosomes as surface-bound cargo. As IL-33 and exosome secretion are both sensitive to 
nSMase2 activity, we next investigated whether IL-33 was in fact associated with exosomes and potentially 
secreted as cargo upon MVE fusion. We concentrated Flag-IL-33Δ34-His–expressing HBE-1 cell supernatant 
with a 100 kDa centrifugal filter, and Western blot analysis revealed that IL-33Δ34 was retained above the fil-
ter, even though free protein (MW 25 kDa) would be expected to flow through (Figure 3E). We then resolved 
exosomes from free proteins by size exclusion chromatography, and Western blot on column fractions 
revealed that IL-33Δ34 signal was absent from exosome fraction 7 but present in free protein fractions 12–15 
(Figure 3E). Recognizing that IL-33 could be oxidized in cell culture media (38), we repeated the experiment 
with fixed, fresh culture supernatant. In fixed supernatant, IL-33Δ34 signal was present in exosome fraction 
7 but migrated at a higher MW (likely as a result of  fixation). We therefore tested whether purified, recom-
binant IL-33Δ34 could bind to separately isolated exosomes. We purified HBE-1 cell–secreted exosomes by 
size exclusion chromatography and incubated with biotinylated IL-33Δ34 protein (Figure 3F). Repeated size 
exclusion chromatography on the mixture demonstrated clear elution of  IL-33Δ34 within exosome fractions 
7–9, highlighted by CD9, and detected by both anti–IL-33 antibody and streptavidin.
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These findings demonstrate that fixation can trap secreted noncovalently bound IL-33Δ34 in complex 
with exosomes in culture supernatant and that exogenously applied IL-33Δ34 can form a stable complex 
with purified exosomes. Collectively, these data illuminate a pathway for IL-33Δ34 secretion, with exosomes 
as surface-bound cargo via the nSMase2-dependent MVE pathway.
Figure 3. IL-33 cosecretion with exosomes as surface-bound cargo. (A) ELISA secretion assay for Flag-IL-33Δ34-His expressing COPD airway basal cells 
treated with nSMase2 activator 4-methylumbelliferone (4-MU, 10 μM) and GW4869 (20 μM). 4-MU augmented secretion, which was blocked by GW4869 (n 
= 5). (B) Live-cell imaging for mCherry-IL33Δ34-GFP HBE-1 cells treated with 4-MU and GW4869 for 15 minutes, demonstrating foci (white arrows) of yellow 
merged signal. HBE-1 cells were also fixed and permeabilized after 15 minutes and imaged for GFP only (green) and immunostained for CD9 (red), demon-
strating foci of colocalization (white arrows). DAPI nuclear counterstain was also used. Scale bar: 10 μm. (C) Secretion of Flag-IL-33full-His from COPD airway 
basal cells was augmented by disruption of nuclear entry (ivermectin, 1 μM) or by nSMase2 activation (4-MU, 10 μM), and both were inhibited by GW4869 (n 
= 5). (D) Live-cell imaging of mCherry-IL-33full-GFP HBE-1 cells treated with DMSO or ivermectin + 4-MU, showing accumulation of cytoplasmic IL-33full signal 
within 1 hour. Hoechst 33342 nuclear counterstain was also used. Scale bar: 10 μm. (E) Exosome and protein fractionation from Flag-IL33Δ34-His–expressing 
HBE-1 cell supernatant (sup). Secreted IL-33 was retained above centrifugal concentrator 100 kDa filter (conc sup) and detected by anti-Flag Western blot. 
Lysate (lys) was used for comparison. Exosomes were resolved from free proteins by a qEV size-exclusion column, and fractions were analyzed: nonfixed 
sup Flag-IL-33Δ34-His resolves into protein fractions and fixed sup protein migrates at a higher MW and resolves into both exosome and protein fractions. (F) 
Purified HBE-derived exosomes (108 particles) incubated for 15 minutes with recombinant site–specific biotinylated IL33Δ34 protein (1 μg) were resolved on 
the qEV column, showing that IL-33 coelutes in CD9-containing exosome fractions without fixation. Data are shown as the mean ± SEM. Statistical analysis: 
1-way ANOVA (A and C); *P < 0.05, **P < 0.01, ***P < 0.001.
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Expression of  the IL33Δ34 isoform in human COPD. To provide context for our in vitro observations, we 
examined human COPD tissue specimens for expression of  IL33 isoforms. We analyzed specimens from 
subjects with very severe COPD undergoing lung transplantation compared with donor lungs unsuitable 
for transplant (non-COPD) (Supplemental Table 1). Using isoform-specific qPCR assays, we observed that 
IL33full and IL33Δ34 isoforms were significantly increased in COPD tissue, unlike IL33Δ3, IL33Δ4, and IL33Δ345 
isoforms, which were detected but not significantly upregulated (Figure 4A and Supplemental Figure 4, 
A and B). To define the expression pattern of  IL33Δ34 in lung tissue, we performed in situ hybridization 
using an isoform-specific probe (Figure 4B and Supplemental Figure 5A). We found IL33Δ34 signal to be 
enriched in cells at the base of  the epithelium in COPD compared with non-COPD tissue (Figure 4B and 
Supplemental Figure 5, C and D), suggesting that airway epithelial basal cells were the primary source of  
increased IL33Δ34 transcript. When the same tissue sections were immunostained for IL-33, protein staining 
could be observed in corresponding regions with high IL33Δ34 probe staining (Supplemental Figure 5D).
To further examine the protein product of  IL33Δ34 in COPD tissue, we analyzed a subset of  non-COPD 
and COPD specimens for which matched tissue sections, protein lysates, and BW samples were available. 
We immunostained tissue sections for IL-33 and the basal cell marker cytokeratin 5 (Krt5) in order to high-
light the cellular localization of  IL-33 protein in COPD airways (Figure 4C and Supplemental Figure 6). 
Representative non-COPD tissues exhibited lower-intensity, predominantly nuclear IL-33 staining patterns 
at the base of  the airway epithelium. In COPD sections, IL-33 staining exhibited variable patterns, including 
intense nuclear and diffuse vesicular patterns as well as a strong signal that colocalized with the cytoplasmic 
basal cell marker Krt5 in one specimen (Figure 4C, COPD 3). We next analyzed these specimens by Western 
blot to characterize the MW of  IL-33 protein products within tissue lysates and BW fluid. We used commer-
cial IL-33 antibodies raised against either NTD (exon 3–4) or CTD (exon 5), which were validated against 
recombinant IL-33 variants (Figure 4D). Western blot in tissue using the CTD antibody shows multiple vari-
able-intensity bands in MW ranges corresponding to IL-33full and IL-33Δ34 in both COPD and non-COPD 
specimens (Figure 4E). NTD antibody staining from tissue lysates could not be interpreted due to high back-
ground signal (data not shown). Parallel analysis of  BW samples demonstrated an approximately 28 kDa 
band of  variable intensity detected by the CTD antibody, but not the NTD antibody, suggesting the absence 
of  exon 3–4 epitope (Figure 4E). IL-33 protein was quantified in equivalent tissue and BW samples (normal-
ized to total protein), revealing significantly elevated IL-33 levels in tissue and a trend toward increased levels 
in BW fluid. Soluble IL-1RL1/ST2 was also quantified and found to be significantly reduced in COPD sam-
ples, suggesting a deficiency in soluble receptor–mediated IL-33 neutralization in COPD BW specimens. 
Among the matched samples in this analysis, COPD 3 was of  particular interest, as this specimen demon-
strated strong cytoplasmic IL-33 signal in tissue, an intense CTD-reactive 28 kDa band on Western blot, and 
the highest IL-33 protein level measured in BW by ELISA (highlighted in yellow, Figure 4, C and E).
Analysis of a separate cohort of cultured airway basal cells also revealed increased IL33full and IL33Δ34 
expression (Figure 4F) compared with that in non-COPD controls. Similar to that in tissue specimens, IL33Δ3, 
IL33Δ4, and IL33Δ345 were detected but not significantly upregulated (Supplemental Figure 4B). Western blot 
analysis on a subset of these cells using NTD and CTD antibodies as above demonstrates again the presence of  
an approximately 28 kDa band reactive with CTD antibody but not NTD, which appears enriched in COPD 
basal cells (Figure 4G). ELISA-quantified IL-33 in the airway cell cohort demonstrates increased total protein 
in COPD airway cell specimens relative to non-COPD, similar to the trend observed in tissue specimens.
Together, these results provide support for enrichment of  the spliced IL33Δ34 isoform in COPD airway 
epithelium, which we have found is capable of  tonic secretion from basal cells. One COPD specimen demon-
strated particularly strong cytoplasmic IL-33 signal in tissues, with concomitant high levels of  a truncated 
protein in BW that exhibited an immunoreactivity profile consistent with the IL33Δ34 variant.
nSMase2 pathway in COPD specimens. nSMase2 metabolizes sphingomyelin to generate ceramide, and both 
lung nSMase2 activity and ceramide metabolism have been shown to be altered in the setting of  cigarette 
smoking (39, 40) and COPD (41–43). We have shown that nSMase2 is increased in COPD airway basal cells 
and regulates tonic IL-33 secretion, and therefore extended the analysis to our cohort of  COPD and non-
COPD tissue specimens. We found that SMPD3 exhibited highly variable expression in lung tissue and was 
increased in multiple COPD specimens, in some by orders of  magnitude (Figure 5A). SMPD3 expression cor-
related with the IL-33 receptor IL1RL1 and the major airway mucin upregulated in COPD, MUC5AC; in some 
samples, these 3 transcripts were coincidentally increased by multiple orders of  magnitude (Figure 5B, boxed 
red data points). Though SMPD3 expression trended higher in COPD tissue samples, this did not translate 
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Figure 4. IL33 isoforms in COPD specimens. (A) IL33 isoform–specific qPCR in lung tissue specimens for IL33full (non-COPD, n = 13; COPD, n = 27) and IL33Δ34 
(non-COPD, n = 12; COPD, n = 23). (B) In situ hybridization in non-COPD and COPD tissues targeting the IL33Δ34 isoform with increased staining in COPD 
tissue (violet). Nuclear fast red counterstain was also used. Scale bar: 50 μm (gray); 10 μm (white). (C) Immunostaining of non-COPD and COPD tissue with 
IL-33 (green) and cytokeratin 5 (Krt5, red), showing variable cytoplasmic IL-33 staining prominent in COPD 3; DAPI counterstain was also used. Scale bar: 
10 μm (white). (D) Epitopes for IL-33 NTD and CTD targeting antibodies and reactivity validated with IL-33 variants expressed in HEK293T cells: IL-33full 38 
kDa (red, 30 kDa degraded band), IL-33Δ34 28 kDa (blue), and IL-33 CTD 17 kDa (black, Peprotech). (E) Matched tissue and bronchial wash (BW) non-COPD (n 
= 3) and COPD (n = 6) specimens. Western blot shows multiple fragments detected by CTD antibody in tissue and a 28 kDa band detected by CTD but not 
NTD antibody in BW. ELISA-quantified IL-33 in the same samples, normalized to total protein. IL-33 protein quantity was increased and soluble ST2 (sST2) 
was decreased in COPD. COPD 3 with the highest level of BW IL-33 protein is highlighted in yellow. (F) IL33 isoform–specific qPCR in airway basal cells for 
IL33full (non-COPD, n = 12; COPD, n = 26) and IL33Δ34 (non-COPD, n = 11; COPD, n = 24) (mean ± SEM). (G) Western blot on a subset of airway basal cell lysates 
showing a 28 kDa band detected in COPD by CTD but not NTD antibody. ELISA-quantified normalized IL-33 protein in non-COPD (n = 12) and COPD (n = 26) 
cells, showing that IL-33 is increased in COPD. Data are shown as the mean ± SEM. Statistical analysis: t test (A, E, F, and G); **P < 0.01.
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to a difference in nSMase2 activity observed in a subset of  specimens, likely in part due to the 10-fold lower 
activity in tissue compared with airway cells (Figure 2C and Figure 5C). Immunohistochemistry and immu-
nofluorescence staining of  nSMase2 and IL-33 in tissue sections demonstrated a patchy basilar pattern in 
non-COPD tissue and a more intense, diffuse staining pattern in COPD tissues (Figure 5, D and E, and Sup-
plemental Figure 7, A and B). Frequently nSMase2-enriched epithelium was coincident with cells exhibiting 
a vesicular cytoplasmic IL-33 pattern that extended toward the airway lumen; examples for multiple COPD 
specimens are shown in Figure 5F. These regions were also stained for the exosome marker CD9 (separately 
due to same antibody host species), which demonstrated a striking linear-reticular pattern surrounding IL-33+ 
basal cells extending to the subepithelial and luminal surfaces; examples are shown in Figure 5G.
Together, these data reveal that SMPD3 expression and nSMase2 protein staining are enriched in 
COPD specimens, and, in some cases, expression was strongly induced concomitant with IL1RL1 and 
Muc5AC. nSMase2 and CD9 staining in proximity to cells exhibiting cytoplasmic and/or vesicular IL-33 
Figure 5. Neutral sphingomyelinase 2 in COPD. (A) SMPD3 qPCR in non-COPD (n = 12) and COPD (n = 26) lung tissue specimens, demonstrating increased expres-
sion in COPD (logarithmic scale due to wide variation in expression level). (B) Pearson’s correlation analysis of SMPD3 versus IL1RL1 and MUC5AC expression. Three 
specimens exhibited high relative expression in COPD compared with non-COPD specimens for all 3 transcripts (red and boxed). (C) Neutral sphingomyelinase 
2 (nSMase2) activity in non-COPD (n = 6) and COPD (n = 14) lung tissue normalized to total protein. (D) Immunohistochemistry in non-COPD and COPD tissue 
stained for nSMase2 (blue) and IL-33 (red); nuclear fast red counterstain was also used. Scale bar: 10 μm. (E) Immunofluorescence staining in non-COPD and COPD 
tissue for nSMase2 (green) and IL-33 (red) with DAPI counterstain. Scale bar: 10 μm. (D and E) Both methods demonstrate increased nSMase2 signal in COPD 
airways. (F) Focal areas of nSMase2 and IL-33 costaining, with punctate cytoplasmic IL-33 pattern extending toward airway lumen (white arrows). Scale bar: 10 μm. 
(G) Immunostaining for IL-33 (red) with CD9 (green) showing variable IL-33 cytoplasmic signal with surrounding reticular CD9 pattern. Scale bar: 10 μm.
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staining patterns suggests the appropriate machinery is in place to facilitate secretion of  IL-33–exosome 
complexes into the airway lumen and interstitium.
Isolation of  IL-33 and exosomes from COPD BW. In parallel with our in vitro analysis of  IL-33 and exo-
somes secreted from cultured airway basal cells, we sought to isolate and characterize endogenous com-
ponents from BW specimens. We performed this analysis with COPD 3 exhibiting the highest IL-33 level, 
first by concentrating the BW sample using a centrifugal 100 kDa filter, as in Figure 3E. Similar to culture 
supernatant, endogenous BW IL-33 was retained above the filter, as quantified in Figure 6A. Concentrat-
ed BW was fractionated by size exclusion chromatography, and ELISA-quantified IL-33 as well as total 
protein levels are shown in Figure 6B. Peak exosome fraction 7 was analyzed by TRPS and DLS (Figure 
6C and Supplemental Figure 3, A and B), yielding vesicle size and distribution nearly identical to those of  
airway cell–derived exosomes, and ultimately confirmed by transmission electron microscopy (Figure 6D). 
Exosome properties were also consistent for multiple COPD specimens evaluated (Supplemental Figure 3, 
B and D). Western blot was performed on BW exosome fraction 7 to verify CD9 positivity and epithelial 
origin based on EpCAM staining (Figure 6E). BW IL-33 largely segregated from exosomes into free protein 
fractions, as observed for nonfixed airway cell supernatant. Western blot using CTD antibody (Figure 6F) 
confirmed the approximately 28 kDa band observed in Figure 4E. IL-33-containing fractions were again 
concentrated (10 kDa filter) and further resolved on a high-resolution Superose 6 size-exclusion column. 
Endogenous IL-33 eluted at a volume corresponding to MW 25 kDa based on standard curve (Figure 6G), 
consistent with the calculated MW of IL-33Δ34. Purified endogenous BW IL-33 was then tested for bioac-
tivity in an HMC 1.2 activation assay (Figure 6, H and I). Due to limited quantities of  purified BW IL-33, 
samples and controls were carefully matched for input concentration before assay (Figure 6H). Endogenous 
BW-derived IL-33 was found to induce IL-8 secretion from HMC 1.2 cells with greater potency than com-
mercial (CTD) protein at the same input concentration (125 pg/ml), which was inhibited by anti–IL-1RL1 
blocking antibody, demonstrating specificity (Figure 6I).
These results collectively reveal that endogenous IL-33 protein isolated from COPD BW fluid exhibits 
biochemical properties consistent with IL-33Δ34 and retains bioactivity. Furthermore, endogenous IL-33 was 
retained with higher-MW species during concentration of BW fluid, similar to IL-33Δ34 secreted from airway 
cells. Exosomes derived from COPD BW specimens also demonstrate a marker profile consistent with epitheli-
al origin, suggesting that the bulk of exosomes secreted into COPD airway surface liquid are epithelial derived.
nSMase2 inhibitor blocks IL-33 secretion and type 2 inflammation in vivo. We have uncovered a mechanism 
for tonic IL-33 secretion from human airway cells in vitro and found support for this model in human 
COPD specimens. To test whether blockade of  nSMase2 activity could disrupt IL-33–mediated inflamma-
tion in vivo, we employed an allergic airway disease model using the fungal allergen Alternaria alternata. 
We selected the Alternaria model for this analysis because it is dependent on IL-33 for induction of  type 2 
inflammation (44–46) and it robustly induces IL-33 protein in BAL fluid (45). Regarding the strategy for 
nSMase2 blockade, the spontaneously derived mouse Smpd3 mutation characterized as fragilitas ossium (fro) 
confers severe developmental abnormalities in mice, including osteogenesis imperfecta and high perinatal 
mortality (47). We therefore chose to focus our efforts on the GW4869 compound that was effective in our 
in vitro studies and has been successfully applied to other inflammatory mouse models (48, 49).
To induce type 2–driven airway disease in mice, we administered 5 doses of  Alternaria extract (or PBS) 
i.n. to mice on alternating days, as an extension of  published protocols (44), and treated mice with either 
GW4869 (Alt/G) or vehicle control (Alt/D) i.p., beginning with the first dose of  Alternaria and adminis-
tering daily thereafter (Figure 7A). At 10 days after Alternaria treatment, lung Il33 and Smpd3 mRNA were 
found to be increased 3-fold in the Alt/D groups and were not significantly reduced with GW4869 treat-
ment (Figure 7B). Induction was limited to Il33, as other type 2 cytokines were not affected by Alternaria 
(Tslp unchanged, Supplemental Figure 8C, and Il25 not detected). Measurement of  IL-33 protein revealed 
a 3-fold induction of  total IL-33 in lung tissue for both Alt/D and Alt/G groups (Figure 7C). In contrast, 
GW4869 appeared to increase intracellular IL-33 protein levels 4-fold in cell suspension, suggesting reten-
tion of  IL-33 in the setting of  nSMase2 blockade. Likewise, IL-33 protein was detected in BAL fluid in the 
Alt/D group at 1 hour and 24 hours following the fifth dose of  Alternaria and was markedly decreased in 
the Alt/G group at both time points. Absolute BAL IL-33 protein was approximately 6-fold higher in BAL 
at the 1-hour versus 24-hour time points (600 pg/ml vs. 100 pg/ml, respectively), which is not reflected by 
normalized levels due to the high BAL protein content immediately following the Alternaria dose. We attri-
bute induced BAL IL-33 protein to secretion rather than cellular necrosis, as the epithelium appears intact 
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at 1 hour (Supplemental Figure 8B) and 24 hours (Supplemental Figure 8A) after Alternaria treatment. 
Likewise, LDH activity in BAL fluid is marginal compared with that in tissue lysate in samples at 1 and 24 
hours, with no observed difference between Alternaria and control groups (Supplemental Figure 8B).
Exosomes isolated from BAL fluid 24 hours after the last Alternaria dose were analyzed by TRPS and 
Western blot. Results for pooled replicates showed that the Alt/D group exhibits increased CD9 signal by 
Western blot and particle number by TRPS, which was decreased to control level with GW4869 treatment. 
Figure 6. Analysis of IL-33 and exosomes from COPD bronchial wash specimens. (A) ELISA quantified IL-33 in concentrated bronchial wash (BW) fluid (100 
kDa filter cutoff) with retention of endogenous IL-33 above the filter. (B) IL-33 and protein concentration measured in fractions eluted from the size-exclu-
sion column (Izon qEV). (C and D) Extracellular vesicles isolated from BW were consistent with exosomes based on transmission electron microscopy (TEM), 
tunable resistive pulse sensing (TRPS), and dynamic light scattering (DLS). Scale bar: 100 nm. (E) Western blot with CD9+ and EpCAM+ exosome fractions, 
indicating an epithelial source. (F) Western blot (CTD antibody) showing elution of truncated IL-33 protein (MW approximately 28 kDa), similar to that shown 
in Figure 4E. See the IL-33 CTD fragment for reference. (G) ELISA analysis of qEV fractions subject to further resolution with Superose6 (Sup6) size exclusion 
chromatography. Elution profile with peak IL-33 in fraction 17 corresponds to MW = 25 kDa based on protein standard curve. (H and I) HMC1.2 activation assay 
for purified endogenous BW IL-33 protein. Input IL-33 concentration for purified protein and CTD standard verified by ELISA due to low BW IL-33 yield. IL-8 level 
in cell supernatant measured by ELISA after 12 hours of incubation with CTD standard, concentrator flow through (FT, negative control), or endogenous IL-33 
with or without IL-1RL1 blocking antibody (100 ng/ml, Proteintech). Data are shown as the mean ± SEM. Statistical analysis: 1-way ANOVA (I); ***P < 0.001.
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Exosome distribution and mean particle size for the Alt/D group were similar to human airway epithelial 
and BW derived exosomes (Figure 7D).
IL-33 immunostaining of  tissue sections demonstrates Alternaria-induced expansion of  IL-33+ paren-
chymal cells with alveolar type 2 morphology (Figure 7E), similar to observations in other IL-33–dependent 
Figure 7. nSMase2 inhibition in Alternaria airway disease model. (A) Schematic of Alternaria experimental model. Mice 
were treated i.n. with 25 μg Alternaria extract (Alt) or PBS (control) every other day for 9 days. Mice receiving Alt were 
either treated i.p. with DMSO/saline vehicle control (Alt/D) or GW4869 (Alt/G, 2–2.5 μg/g) daily for 9 days. Some mice 
were analyzed 1 hour following the last Alt dose; the remainder were analyzed 24 hours after the last dose. (B) Lung tissue 
qPCR for the 3 groups (n = 3), demonstrating increased Il33 and Smpd3 mRNA with Alt treatment. (C) IL-33 protein quan-
tified by ELISA (normalized to total protein) for lung lysate (n = 3), intracellular fraction (pooled single-cell suspension, n = 
3 each), and 1-hour (n = 3) or 24-hour (n = 3) bronchoalveolar lavage (BAL) samples. IL-33 was increased in the intracellular 
fraction and decreased in BAL with GW4869 treatment. (D) Exosome quantity measured by TRPS for pooled (n = 3) BAL 
samples with vesicle quantity, representative size distribution (with peak), and CD9 Western blot, reflecting the decrease 
in BAL vesicle quantity and corresponding CD9 staining with GW4869 treatment. (E) Tissue IL-33 immunofluorescence 
staining (red) demonstrating increased cytoplasmic IL-33 signal (insets) and expansion of IL-33+ parenchymal cells in Alt 
groups. DAPI counterstain was also used. Scale bar: 50 μm (gray); 10 μm (white). (F) Lung tissue Il13 and Il5 qPCR (n = 3) 
demonstrating induction with Alt treatment that was attenuated with GW4869. (G) Representative FACS plots for sorted 
lung innate lymphoid type 2 cells (ILC2, pooled samples, n = 3) and Il13 qPCR in sorted cells, demonstrating induction of 
ILC2 cells and IL13 expression with Alt treatment and concomitant reduction with GW4869 treatment. Data are shown as 
the mean ± SEM. Statistical analysis: 1-way ANOVA (B, C, and F); *P < 0.05, **P < 0.01, ***P < 0.001.
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airway disease models (9). This effect was observed in both Alt/D and Alt/G groups, consistent with 
GW4869 mediating blockade of  IL-33 secretion rather than expression. In control tissue, IL-33 exhibited 
a predominant nuclear pattern, whereas in the Alt/D and Alt/G groups, many cells exhibited a mixed 
nucleocytoplasmic IL-33 staining pattern (Figure 7E).
With respect to IL-33–induced type 2 inflammation, we analyzed the model at the 6- and 10-day time 
points and found a 15-fold induction of  lung Il13 mRNA at 6 days (3 doses) and 100-fold at 10 days (5 dos-
es) (Figure 7F and Supplemental Figure 8C). Subsequent analyses were therefore performed at the 10-day 
time point. In addition to Il13, lung Il5 was also increased 5-fold, and both were substantially decreased 
with GW4869 treatment. Likewise, lungs sorted for IL-1RL1+/Thy1.2+ innate lymphoid type 2 (ILC2) cells 
demonstrated induction of  ILC2s in the Alt/D group, which was partially blocked in the Alt/G group (Fig-
ure 7G). Analysis of  Il13 expression in sorted cells from pooled replicates demonstrates a 2-fold increase 
in Alt/D group that was reduced to control level in Alt/G group. We observed a mild increase in Muc5ac 
6 days after Alternaria treatment, which was further induced at 10 days and was augmented with GW4869 
treatment (Supplemental Figure 8C). While qualitatively PAS staining appeared diminished in Alt/G tis-
sue sections (Supplemental Figure 8A), it is possible that other IL-33–independent pathways contributing 
to mucus production are induced in this model (50).
Together, these findings support our model developed in the human system implicating the nSMase2- 
dependent exosome biogenesis pathway in lung epithelial IL-33 secretion. Disruption of  type 2 inflamma-
tion in this model is not based on a substantial reduction in Il33 expression, but rather inhibition of  IL-33 
secretion, implicating a potentially novel pathway in IL-33–induced chronic airway disease, which we have 
shown to be amenable to therapeutic intervention.
Discussion
This study addresses multiple fundamental questions in the field of  IL-33 biology and advances our under-
standing of  human chronic airway disease pathogenesis. We show that the IL-33Δ34 isoform is increased 
in COPD and can undergo tonic secretion from airway cells independent of  proteolytic processing. We 
found that this mechanism of  secretion from intact airway cells is applicable to all IL-33 variants and 
occurs through the nSMase2-dependent MVE pathway. Remarkably, IL-33 appears to be secreted as a 
surface-bound rather than an encapsulated exosome cargo. Identification of  nSMase2 as a key mediator of  
IL-33 secretion and demonstration of  increased nSMase2 expression in COPD specimens provides a con-
nection between environmental triggers and nonclassical inflammatory cytokine secretion. We furthermore 
highlight a therapeutic angle for disrupting the IL-33 system by demonstrating that nSMase2 inhibition can 
block IL-33 secretion and subsequent type 2 inflammation in a mouse model of  airway disease.
Our investigation revealed that tonic secretion of the IL-33Δ34 isoform is dependent on the exosome biogen-
esis pathways regulated by nSMase2. In the context of prior work, multiple stimuli for IL-33 release have been 
described based on the alarmin hypothesis, including cryoshock (51), proteases (19), respiratory viral infection 
(52, 53), and allergens, including house dust mite (54). Comparatively, Alternaria extract has been reported to 
induce alarmin release via cellular necrosis (55) or regulated secretion involving purinergic receptors, intra-
cellular calcium signaling, and reactive oxygen species (56, 57). We have also observed modest amounts of  
endogenous IL-33 secreted from intact airway basal cells exposed to exogenous ATP (9). One common theme 
among these stimuli is that they all can induce EV flux as a cellular prosurvival signal (58). Therefore, it is 
possible that a diverse array of cellular signals could converge upon a fundamental cellular pathway that medi-
ates nonclassical protein and exosome secretion. In this case, it appears such a pathway is co-opted by dys-
regulated IL33 isoforms expressed in chronic airway disease. It is our expectation that IL-33 would not be the 
only inflammatory mediator to utilize such a secretory mechanism, indeed this may be a shared phenomenon 
among IL-1 family members (59, 60). Future studies of nonclassical cytokine secretion will be greatly informed 
by a more thorough understanding of functional compensation between ESCRT-dependent and -independent 
MVE pathways and their intersection with chaperone-mediated microautophagy.
The results presented here provide key mechanistic insights into a potential role for EV-mediated cellular 
communication in chronic airway disease pathogenesis. Indeed, exosome biogenesis pathways have previous-
ly been linked to chronic lung disease (61) and nSMase2 has been associated with eosinophilic asthma (62) 
and found to be increased along with ceramide metabolites in smokers (43) and COPD (42). We have found 
that nSMase2 is increased COPD specimens and propose a model by which nSMase2 regulates secretion of  
IL-33 as surface-bound exosome cargo. It will be important going forward to define the molecular interactions 
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between cytoplasmic IL-33 and chaperones that recruit this cytokine to the MVE pathway. Likewise, it will 
be necessary to determine what role exosome-bound IL-33 plays in the efficiency of  IL-33 receptor signaling 
on effector cells. Future studies should also address whether exosomes can enhance IL-33 stability, given the 
propensity of  this cytokine to be inactivated by protease digestion or oxidation in the extracellular milieu (38).
With respect to the endogenous form of  IL-33, our analysis of  COPD BW IL-33 protein indicates that 
a truncated bioactive form is present, with an antibody reactivity profile consistent with the IL-33Δ34 iso-
form. Several prior studies have examined the issue of  IL-33 processing, mostly in the context of  IL-33full 
protein. The flexible linker region encoded by exon 4 is not a substrate of  caspase-1, in contrast to IL-1β 
and IL-18 (17, 19, 20), but is sensitive to multiple inflammatory proteases. Given that the secreted IL-33Δ34 
isoform lacks the protease-sensitive exon 4 linker, it is not surprising that we observe the protein to be 
secreted in an intact form. Definitive characterization of  endogenous IL-33 will require mass spectrome-
try–based analysis of  sufficient quantities of  highly purified (nondegraded) protein from relevant biologi-
cal specimens, which remains a challenging endeavor.
Regarding the limitations of  our approach, we understand that our in vitro observations have been made 
in the context of  protein overexpression, which has limitations and could produce unexpected artifacts in 
any system. We have conducted our experiments carefully to address the phenomenon with different tagged 
formats and diseased/nondiseased primary cells and cell lines and under a range of  expression levels and 
culture formats to address any irregularities that may result from these experimental conditions.
With respect to our in vivo model, we recognize that COPD is a heterogeneous disorder with multiple 
described inflammatory endotypes (63), among them type 2 predominant asthma-COPD overlap syndrome 
(64). Clear challenges remain in defining and validating these endotypes in research and clinical care. In 
choosing a model system for this study, we considered factors, including variable severity of  phenotype 
(smoking), strain and/or pathogen-specific responses (virus), and distinct respiratory anatomy in mice and 
humans (IL-33 expression in type 2 pneumocytes in mice vs. basal cells in humans). Multiple studies to 
date have implicated IL-33 in Alternaria-induced respiratory disease and have identified this fungal allergen 
as a potent stimulus for IL-33 secretion in BAL fluid in vivo. With this in mind, we established the Alter-
naria model to test respiratory IL-33 secretion and downstream inflammation with disruption of  nSmase2 
activity. We recognize that this model does not encompass the full spectrum of  COPD disease.
Clinical COPD care would indeed benefit from a better understanding of  which patients may respond 
more favorably to therapies targeting specific inflammatory endotypes. Our COPD cohort includes suffi-
cient material to explore disease mechanism but is composed of  severe COPD specimens, which limits our 
ability to correlate IL-33Δ34 or nSMase2 with COPD disease severity or expression-based metrics of  type 2 
endotypes (65). Future investigation and validation of  pathways illuminated in this study will require the 
addition of  specimens across the spectrum of  disease severity and endotypes that incorporate protein- and 
exosome-focused sampling methods.
In summary, our analysis in human COPD illuminates a role for nSMase2 and exosome pathways in the 
mechanism of IL-33 airway secretion, supported by amelioration of  type 2 inflammation with pharmacologi-
cal blockade of  nSMase2 in vivo. This work reveals a potentially novel aspect of  IL-33 biology with the poten-
tial to open a new area of  investigation in chronic airway disease and development of  COPD therapeutics.
Methods
Additional details are provided in the Supplemental Methods. Details for all materials and reagents used in 
this study are provided in Supplemental Table 2.
Human lung samples and study design. Clinical samples were obtained from consenting patients at the time 
of  lung transplantation from COPD recipients (n = 27) with very severe disease (GOLD stage IV) during the 
period from 2011 to 2019 at Barnes-Jewish Hospital. Control samples were obtained from non-COPD donor 
lungs (n = 13) that were not usable for transplantation at Barnes-Jewish Hospital and University of  Nebraska 
Medical Center. There were no predetermined inclusion or exclusion criteria beyond criteria for lung trans-
plant candidacy. To analyze tissue staining, gene expression, and protein levels, lung tissue samples were col-
lected and processed for histopathology and RNA and protein analysis from 4 different lung zones of  each 
specimen. For this study, equivalent quantities of  the 4 lung areas were pooled for RNA and protein analysis 
to represent a single sample per specimen. Tissue was homogenized in TRIzol (Invitrogen) for all COPD (n 
= 27) and non-COPD (n = 13) specimens for RNA extraction. COPD (n = 14) and non-COPD (n = 6) spec-
imens were minced and lysed in T-PER (Pierce) supplemented with HALT protease inhibitor (Pierce) and 
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centrifuged at 10,000g, and supernatant collected for protein analysis. COPD (n = 14) and non-COPD (n = 
6) tissue specimens were fixed in 10% neutral buffered formalin (Thermo Fisher) before paraffin embedding 
and sectioning for histopathology analysis. Airway basal cells were cultured from large airways (first to third 
generation) for COPD (n = 26) and non-COPD (n = 12) specimens, and cells were processed for RNA and 
protein analysis. For a subset of  COPD (n = 6) and non-COPD (n = 3) specimens, BW was also performed 
at the time of  specimen collection above. BW fluid was obtained from explanted lungs by gently injecting 
100 ml PBS into mainstem bronchi, and fluid was recovered with passive return and gentle suctioning (to 
preferentially return airway surface liquid and minimize alveolar lavage). BW fluid was centrifuged at 100g 
to pellet cells, and HALT was added to supernatant before storage for further analysis.
Exosome preparations and analysis. EVs were isolated from BW fluid and cell culture supernatants in an 
analogous manner. Solutions were first spun at 2000g to clarify, followed by concentration using a centrifugal 
concentrator with 100 kDa MW cutoff  (Sartorius Vivaspin Turbo). For low-abundance samples (mouse BAL 
fluid, shRNA knockdown), samples of  equivalent volumes were analyzed following the concentration step. 
For samples of  larger quantity (culture supernatants), equivalent volumes of  supernatant from confluent cul-
tures were concentrated and fractionated on a qEV 35 (Izon Science) size-exclusion column. Fractions were 
collected in PBS supplemented with HALT protease inhibitor and screened by DLS (Malvern NanoS) to 
verify vesicle size and homogeneity (polydispersity index). Exosomes (100–150 nm) typically eluted in frac-
tion 7–8 and free proteins in fractions 12–17 when run according to manufacturer protocol. For experiments 
conducted under fixed conditions, following clarification supernatant was fixed with 1% paraformaldehyde 
for 5 minutes at room temperature and quenched with 1 M Tris pH 8.0. Supernatant was then concentrated 
similar to the nonfixed sample and exosomes were purified using the qEV 35 column; exosome integrity 
(size, homogeneity) was verified post-fixation. For purified exosomes mixed with recombinant biotinylated 
IL-33Δ34 protein, approximately 1 × 108 HBE-derived exosomes were incubated with 1 μg IL-33Δ34-biotin in 
100 μl PBS for 15 minutes at room temperature. Samples were then purified on a qEV 35 column as above.
Exosome analysis was performed using a combination of  DLS, transmission electron microscopy, 
and TRPS. Human and mouse exosomes were typically concentrated 10-fold and quantified by TRPS 
(Izon Biosciences qNano device) using a 150 nm cutoff  pore filter (NP150) and by DLS (Malvern NanoS). 
Human COPD 3 BAL-derived exosomes were purified by qEV 35 column as above and prepared per ref. 66 
for imaging on a JEOL JEM-1400 120 kV transmission electron microscope with an Advance Microscopy 
Technologies camera system.
IL-33 secretion assays. Primary airway basal cells from non-COPD and COPD specimens and HBE-1 cell 
line were cultured as described in Supplemental Methods on collagen-coated tissue culture plates (unless 
otherwise indicated). All secretion assays were performed at 37°C and 5% CO2. Media were exchanged to 
fresh prewarmed BEGM at beginning of  assay, and plates were incubated for 2 hours. Supernatant was 
clarified and cells were lysed in MPER (Pierce) supplemented with HALT protease inhibitor (Pierce). For 
all secretion assays, IL-33 protein was quantified in supernatant and lysate using R&D commercial ELISA 
assays (Supplemental Methods) with total assay protein (supernatant + lysate) and percentage secretion 
(supernatant/[supernatant + lysate] × 100) quantified based on standard curve. Some experiments were 
performed in polarized format using Transwell culture dishes (0.4 μm and 1.0 μm pore size). Calculations 
were performed similarly for polarized format, with total assay protein (apical + basal + lysate) and per-
centage secretion (apical or basal/[apical + basal + lysate] × 100).
For chemical inhibition assays, all chemicals were solubilized in DMSO and filter sterilized before use. 
As a control, DMSO was used at the highest concentration required for solubility in the assay. Inhibitors 
were preincubated with cells for 1 hour before beginning secretion assay and maintained in media during 
assay. Chemical concentrations used for inhibition assay were as follows: PBS; DMSO vehicle control 
(2.5%); BD GolgiPlug Brefeldin (1:1000), GolgiStop Monensin (1:1500), GW4869 (20 μM), Cambinol (10 
μM), Spiroepoxide (5 μM), glutathione (5 μM), and 3-MA (5 μM) (manufacturer information and product 
number for chemicals are provided in Supplemental Table 2).
All secretion assays were performed with n = 5 biological replicates (unless otherwise indicated) and 
performed in triplicate.
Alternaria mouse model. WT 5-week-old male C57Bl/6 mice were purchased from The Jackson Labora-
tory. Alternaria alternata extract was purchased from Greer Laboratories and reconstituted and adjusted to 1 
mg/ml solution in sterile saline (based on BCA assay, Pierce). GW4869 (N,N′-Bis[4-(4,5-dihydro-1H-imid-
azol-2-yl)phenyl]-3,3′-p-phenylene-bis-acrylamide dihydrochloride; MW 577.5 g/mol; MilliporeSigma) was 
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reconstituted in DMSO (20 mg/mL stock) and diluted into sterile saline before use. Experiments included 
n = 11–14 mice per group and were repeated in triplicate. Five-week-old mice were either treated with 25 μg 
i.n. Alternaria extract (in 25 μl) or PBS control (25 μl) under isoflurane anesthesia every 48 hours for a total of  
5 doses over 9 days. Mice in Alternaria groups were also treated with 100 μl of  0.5 mg/mL GW4869 in 2.5% 
DMSO/saline (50 μg/mouse; 2–2.5 μg/g body weight) or 100 μl of  2.5% DMSO/saline vehicle control 
every 24 hours for 9 days, beginning on the same day as the first dose of  Alternaria. Mice were analyzed 24 
hours after the final Alternaria dose, except for 1 hour after Alternaria BAL, for which mice were analyzed 1 
hour after the fifth dose. No behavioral problems were observed during treatment. Mild body weight loss was 
observed in both Alternaria treatment groups (5%–10%), which was not different between groups and recov-
ered by the end of  the experiment. RNA extraction, qPCR and ELISA, and cell sorting are described in Sup-
plemental Methods; tissue and cell preparations were lysed in TRIzol or TPER/HALT (Pierce) for analysis. 
BAL fluid was obtained by intratracheal instillation of  0.7 ml PBS with return volume of  approximately 
0.3–0.4 mL, and samples were centrifuged to pellet cells. Supernatants from n = 3 mice were analyzed by 
ELISA (mouse IL-33 DuoSet, R&D Systems) (normalized to total protein by BCA assay), and an equivalent 
volume of  each replicate BAL supernatant was combined and concentrated with a 100 kDa concentrator 
and the pooled specimens were analyzed by TRPS and Western blot. Mouse Alternaria model experiments 
were performed with accompanying analysis in triplicate.
Statistics. For statistical analysis, 2-tailed Student’s t test was used for comparisons between 2 groups, and 
comparisons with 3 or more groups were analyzed using 1-way ANOVA. For all experiments, P < 0.05 was 
considered statistically significant. Correlation analysis was performed based on Pearson’s coefficient. For 
all data in which 3 or more independent measurements are reported, data are displayed as mean ± SEM.
Study approval. All human studies were conducted with protocols approved by the Washington Uni-
versity Institutional Review Board, and written informed consent was obtained from study participants. 
All experiments involving animals followed protocols approved by Washington University’s Institutional 
Animal Care and Use Committee.
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